American Capital Management Inc. Sells 7,500 Shares of Haemonetics Corporation $HAE

American Capital Management Inc. cut its stake in Haemonetics Corporation (NYSE:HAE) by 10.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 66,915 shares of the medical instruments supplier’s stock after selling 7,500 shares during the quarter. American Capital Management Inc. owned about 0.14% of Haemonetics worth $3,771,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Haemonetics by 3.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock worth $1,877,000 after purchasing an additional 971 shares during the last quarter. Caxton Associates LLP bought a new stake in Haemonetics during the first quarter valued at about $216,000. United Services Automobile Association purchased a new position in Haemonetics in the first quarter valued at about $212,000. Empowered Funds LLC grew its stake in Haemonetics by 9.1% in the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock valued at $283,000 after purchasing an additional 372 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Haemonetics by 6.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after purchasing an additional 9,051 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Stock Up 1.6%

HAE stock opened at $80.06 on Tuesday. The firm has a 50 day moving average of $73.21 and a 200 day moving average of $66.04. The stock has a market capitalization of $3.64 billion, a PE ratio of 39.64, a price-to-earnings-growth ratio of 1.59 and a beta of 0.52. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. Haemonetics Corporation has a 52 week low of $47.31 and a 52 week high of $87.32.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The company had revenue of $346.35 million for the quarter, compared to the consensus estimate of $336.83 million. During the same quarter in the previous year, the firm earned $1.24 EPS. Haemonetics’s revenue was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Sell-side analysts forecast that Haemonetics Corporation will post 5.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on HAE shares. JPMorgan Chase & Co. decreased their price target on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Bank of America raised shares of Haemonetics from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $72.00 to $80.00 in a research report on Friday, May 22nd. Weiss Ratings upgraded shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, June 25th. Mizuho increased their target price on shares of Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Finally, Citigroup restated a “neutral” rating on shares of Haemonetics in a research note on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $78.89.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.